logo

For the Inventor, By the Inventor

Portland, OR, United States of America

Milton Yatvin

This inventor holds 24 USPTO granted patents, primarily in Drug Delivery Technologies. Top assignees: Oregon Health & Science University, Enzrel Inc., State of Oregon. Active years: 1992-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Milton Yatvin. Retrieved from https://idiyas.com/inventor/milton-yatvin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24

% Patents Active = 66.7

Average Co-Inventor Count = 2.4

ph-index = 12

Forward Citations = 954(Granted Patents)


Company Filing History:

goldMedal11 out of 526 
 
Oregon Health & Science University
 patents
silverMedal6 out of 6 
 
Enzrel Inc.
 patents
bronzeMedal5 out of 199 
 
State of Oregon
 patents
4. 2 out of 2 
 
Oradel Medical Ltd.
 patents

Years Active: 1992-2008

Loading Chart...
Areas of Expertise:
Nonporous Microparticle
Prodrug Conjugates
Liposome Delivery
Biologically-Active Compounds
Anti-Mycobacterial
Covalent Conjugates
Antioxidant Compounds
Amino Acid Derivatives
Targeting Mechanisms
Drug Targeting
Polycyclic Compounds
Microparticle Conjugates
24 patents (USPTO):Explore Patents
1. 7423010 - Nonporous microparticle-prodrug conjugates for treatment of infection (2008-09-09),
2. 7387791 - Liposome drug delivery (2008-06-17),
3. 7316818 - Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds (2008-01-08),
4. 7045543 - Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites (2006-05-16),
5. 6858582 - Composition containing porous microparticle impregnated with biologically-active compound for treatment of infection (2005-02-22),
6. 6824790 - Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds (2004-11-30),
7. 6761901 - Liposome drug delivery (2004-07-13),
8. 6689760 - Anti-mycobacterial compositions (2004-02-10),
9. 6676972 - Covalent microparticle-drug conjugates for biological targeting (2004-01-13),
10. 6664257 - Anti-mycobacterial compounds (2003-12-16),
11. 6455073 - Covalent microparticle-drug conjugates for biological targeting (2002-09-24),
12. 6436437 - Covalent polar lipid conjugates with neurologically active compounds for targeting (2002-08-20),
13. 6387876 - Covalent polar lipid-conjugates with biologically active compounds for use in salves (2002-05-14),
14. 6339060 - Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting (2002-01-15),
15. 6063759 - Conjugate of biologically active compound and polar lipid conjugated to (2000-05-16),

Title: The Innovative Journey of Milton B Yatvin

Introduction: Milton B Yatvin, a pioneering inventor based in Portland, Oregon, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Milton B Yatvin holds several patents in various technological domains, showcasing his continuous dedication to innovation and creativity.

Career Highlights: With a career spanning over two decades, Milton B Yatvin has established himself as a prominent figure in the tech industry, known for his forward-thinking approach and problem-solving abilities.

Collaborations: Throughout his career, Milton B Yatvin has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life and make a lasting impact on the industry.

Conclusion: Milton B Yatvin's passion for innovation and his relentless pursuit of technological advancement have solidified his reputation as a visionary inventor, shaping the future of technology one patent at a time.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…